Intrapatient Evolutionary Dynamics of Human Immunodeficiency Virus Type 1 in Individuals Undergoing Alternative Treatment Strategies with Reverse Transcriptase Inhibitors

被引:0
|
作者
Kayondo, Jonathan K. [1 ]
Ndembi, Nicaise [2 ]
Parry, Chris M. [2 ]
Cane, Patricia A. [3 ]
Hue, Stephane [4 ]
Goodall, Ruth [5 ]
Dunn, David T. [5 ]
Kaleebu, Pontiano [1 ,2 ]
Pillay, Deenan [4 ]
Mbisa, Jean L. [3 ]
机构
[1] Uganda Virus Res Inst, Uganda Res Unit AIDS, Entebbe, Uganda
[2] UVRI, MRC, Uganda Res Unit AIDS, Entebbe, Uganda
[3] Publ Hlth England, Virus Reference Dept, London, England
[4] UCL, Dept Infect & Immun, London, England
[5] UCL, MRC, Clin Trials Unit, London, England
基金
英国惠康基金;
关键词
DRUG-RESISTANCE; HIV; INTERRUPTION; INFECTION;
D O I
10.1089/aid.2015.0035
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Structured treatment interruption (STI) has been trialed as an alternative to lifelong antiretroviral therapy (ART). We retrospectively performed single genome sequencing of the HIV-1 pol region from three patients representing different scenarios. They were either failing on continuous therapy (CT-F), failing STI (STI-F), or suppressing on STI (STI-S). Over 460 genomes were generated from three to five different time points over a 2-year period. We found multiple-linked-resistant mutations in both treatment failures. However, the CT-F patient showed a stepwise accumulation of diverse, linked mutations whereas the STI-F patient had lineage turnover between treatment periods with recirculation of wild-type and resistant variants from reservoirs. The STI-F patient showed a 7-fold increase in the third codon position substitution rate relative to the first and second positions compared to a 2-fold increase for CT-F and increased purifying selection in the pol gene (62 vs. 22 sites, respectively). An understanding of intrapatient viral dynamics could guide the future direction of treatment interruption strategies.
引用
收藏
页码:749 / 756
页数:8
相关论文
共 50 条
  • [1] Recombinant human immunodeficiency virus type 1 reverse transcriptase is heterogeneous
    Wilson, JE
    Wright, LL
    Martin, JL
    Haire, SE
    Ray, PH
    Painter, GR
    Furman, PA
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1996, 11 (01): : 20 - 30
  • [2] Rational Approaches for the Design of Effective Human Immunodeficiency Virus Type 1 Nonnucleoside Reverse Transcriptase Inhibitors
    Ribone, Sergio R.
    Quevedo, Mario A.
    Madrid, Marcela
    Brinon, Margarita C.
    JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2011, 51 (01) : 130 - 138
  • [3] Ribonucleoside Triphosphates as Substrate of Human Immunodeficiency Virus Type 1 Reverse Transcriptase in Human Macrophages
    Kennedy, Edward M.
    Gavegnano, Christina
    Nguyen, Laura
    Slater, Rebecca
    Lucas, Amanda
    Fromentin, Emilie
    Schinazi, Raymond F.
    Kim, Baek
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (50) : 39380 - 39391
  • [4] Etravirine and Rilpivirine: Nonnucleoside Reverse Transcriptase Inhibitors with Activity Against Human Immunodeficiency Virus Type 1 Strains Resistant to Previous Nonnucleoside Agents
    Fulco, Patricia Pecora
    McNicholl, Ian R.
    PHARMACOTHERAPY, 2009, 29 (03): : 281 - 294
  • [5] STRUCTURE OF THE BINDING-SITE FOR NONNUCLEOSIDE INHIBITORS OF THE REVERSE-TRANSCRIPTASE OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1
    SMERDON, SJ
    JAGER, J
    WANG, J
    KOHLSTAEDT, LA
    CHIRINO, AJ
    FRIEDMAN, JM
    RICE, PA
    STEITZ, TA
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (09) : 3911 - 3915
  • [6] Dipyridodiazepinone Analogs as Human Immunodeficiency Virus Type 1-Specific Non-Nucleoside Reverse Transcriptase Inhibitors: An Overview
    Lv, M.
    Xu, H.
    CURRENT MEDICINAL CHEMISTRY, 2010, 17 (18) : 1874 - 1898
  • [7] Stabilization of human immunodeficiency virus type 1 reverse transcriptase by site-directed mutagenesis
    Kosaku Nishimura
    Mayu Shinomura
    Atsushi Konishi
    Kiyoshi Yasukawa
    Biotechnology Letters, 2013, 35 : 2165 - 2175
  • [8] Stabilization of human immunodeficiency virus type 1 reverse transcriptase by site-directed mutagenesis
    Nishimura, Kosaku
    Shinomura, Mayu
    Konishi, Atsushi
    Yasukawa, Kiyoshi
    BIOTECHNOLOGY LETTERS, 2013, 35 (12) : 2165 - 2175
  • [9] HIGHLY SPECIFIC INHIBITORS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 WHICH ARE PARTICULARLY TARGETED AT THE REVERSE-TRANSCRIPTASE
    DECLERCQ, E
    SNOECK, R
    PATHOLOGIE BIOLOGIE, 1993, 41 (03): : 230 - 236
  • [10] Suppression of human immunodeficiency virus replication in human brain tissue by nucleoside reverse transcriptase inhibitors
    Apsara Kandanearatchi
    Annapurna Vyakarnam
    Sabine Landau
    Ian Paul Everall
    Journal of NeuroVirology, 2004, 10 : 136 - 139